BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNHGlobeNewsWire • 07/15/21
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from BaselineGlobeNewsWire • 07/10/21
ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid CongressGlobeNewsWire • 07/01/21
BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of HealthGlobeNewsWire • 06/16/21
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?Zacks Investment Research • 05/18/21
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema PatientsGlobeNewsWire • 05/12/21
Strength Seen in BioCryst (BCRX): Can Its 21% Jump Turn into More Strength?Zacks Investment Research • 05/07/21
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo RevenuesBenzinga • 05/06/21
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 05/06/21
BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema PatientsGlobeNewsWire • 04/30/21